Author: Mabwell Therapeutics $412.5 million! Mabwell Announces Exclusive Licensing Agreement with DISC MEDICINE, INC. for Innovative Drug Candidates of Hematologic Diseases Read More Mabwell Announces the NMPA approval of 9MW3011 (FIC) for IND Read More Mabwell Announces the U.S. FDA approval of 9MW3011 (FIC) for IND Read More Mabwell is Officially Listed on the Shanghai Stock Exchange STAR Market Read More China’s First Anti-Nectin-4 ADC Drug Receives IND Approval Read More First China-made Anti-ST2 Antibody Developed by Mabwell Approved for Clinical Study Read More Mabwell participated in the Shanghai Biopharmaceutical Industry Innovation Alliance as the Secretary-General Read More Mabwell Closes Series A Financing of 1.97 Billion Yuan to Speed Up New Variety R&D and Industrialization Read More